Mar 16, 2023
AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

Mar 08, 2023
AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease

Mar 06, 2023
AIM ImmunoTech Issues Letter to Stockholders

Feb 28, 2023
AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients

Feb 17, 2023
AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, "Long Covid: What Will It Take To Accelerate Therapeutic Progress?"

Jan 17, 2023
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center

Jan 09, 2023
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention

Jan 05, 2023
AIM ImmunoTech to Present at the 'Virtual Investor 2023 Companies to Watch Event'

Dec 12, 2022
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer

Dec 08, 2022
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects

 2   3   4   5   6     7    8   9   10   11   12